UniDoc - Announces Filing of Amended and Restated Interim Management Discussion and Analysis

Rhea-AI Summary

UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) announced it has filed an amended and restated Management's Discussion and Analysis (MD&A) for the six-month period ended September 30, 2024, following a continuous disclosure review by the British Columbia Securities Commission.

The company has revised its interim MD&A to include clarifying disclosure on four key areas: the nature of UniDoc's business, recent developments, contractual agreements, and explanations relating to advertising costs incurred by the company.

Shareholders can access the amended and restated MD&A under UniDoc's issuer profile on SEDAR+ at www.sedarplus.ca. The announcement was made on behalf of the Board of Directors by Antonio Baldassarre, who serves as CEO, President & Director of UniDoc Health Corp.

Positive

• None.

Negative

• Regulatory scrutiny from British Columbia Securities Commission requiring amended filings
• Disclosure issues requiring clarification of company's business nature, developments, and expenses

VANCOUVER, BC / ACCESS Newswire / February 24, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company"), is issuing this news release to advise its shareholders that the Company has been subject to a continuous disclosure review by the British Columbia Securities Commission. In connection therewith, the Company has filed amended and restated management's discussion and analysis ("MD&A") for the six (6) month period ended September 30, 2024, to clarify its disclosure.

Amended and Restated Management's Discussion and Analysis

The Company has amended and restated its interim management's discussion and analysis for the six (6) month period ended September 30, 2024, to include the following clarifying disclosure:

1. nature of the Company's business;

2. recent developments;

3. the Company's contractual agreements; and

4. explanation relating to advertising cost incurred by the Company.

The amended and restated MD&A has been filed under the Company's issuer profile on SEDAR+ at www.sedarplus.ca.

On Behalf of the Board of Directors,

~Antonio Baldassarre~

Antonio Baldassarre
CEO, President & Director
UniDoc Health Corp.

About UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF)
UniDoc is developing an eHealth solution which is being designed as a self-contained remote virtual clinic within a private kiosk for patients to undergo full consultations as if they were present in a physician's office. eHealth opens the doors to a large segment of the population challenged by access, experience or understanding of online computer technology. It is the Company's belief that physical accessibility is the key to its business proposition. UniDoc is dedicated to unlocking shareholder value by delivering an excellent product and sophisticated commercial network within an expedited timeframe. The UniDoc team encourages engagement, questions, and interest, so please stay in touch and invite anyone who might be interested in our story to visit our website at www.unidoctor.com and signup to receive the latest information with updates on our activities, events and progress.

For further information, please contact:
UniDoc Investor Relations
Tel: +1 778.383.6731
Email: info@unidoctor.com

Matt Chatterton, Director
Tel: +1 778.613.2082
Email: matt@unidoctor.com

Media Inquiries media@unidoctor.com

Forward-Looking Statements
This news release contains statements and information that, to the extent that they are not historical fact, may constitute "forward-looking information" within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as "may", "would", "could", "will", "will be", "likely", "except", "anticipate", "believe", "intend", "plan", "forecast", "project", "estimate", "outlook", or the negative thereof or other similar expressions concerning matters that are not historical facts.

Forward-looking information is based on the assumptions, estimates, analysis, and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; the Company's ability to secure additional financing on reasonable terms; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all; as well as all of the other risks as described in the Company's annual management discussion and analysis dated July 31, 2024 under the heading "Risks Factors." Accordingly, readers should not place undue reliance on any such forward-looking information.

Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company's management to predict all such factors and to assess in advance the impact of each such factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: UniDoc Health Corp.

View the original press release on ACCESS Newswire

FAQ

Why did UDOCF file an amended MD&A for September 2024?

UniDoc (UDOCF) filed an amended MD&A following a continuous disclosure review by the British Columbia Securities Commission, to clarify disclosure on its business nature, recent developments, contractual agreements, and advertising costs.

What specific areas did UDOCF need to clarify in its amended MD&A filing?

UniDoc needed to clarify four specific areas: the nature of its business, recent developments, contractual agreements, and explanations relating to advertising costs incurred by the company.

When was UniDoc's amended MD&A filed and where can investors access it?

UniDoc's amended MD&A for the six-month period ended September 30, 2024 was announced on February 24, 2025, and can be accessed under the company's issuer profile on SEDAR+ at www.sedarplus.ca.

What regulatory body conducted the continuous disclosure review of UDOCF?

The British Columbia Securities Commission conducted the continuous disclosure review of UniDoc Health Corp. that led to the amended filing.

What impact might the UDOCF disclosure review have on investors?

The disclosure review indicates regulatory scrutiny and potential previous disclosure inadequacies, which might raise governance concerns for investors, though the company has now addressed these issues with the amended filing.